|Grant Affiliation:||Farzan: Preventing HIV-1 transmission with a novel entry inhibitor, eCD4-Ig|
|Strategy:||Prophylactic neutralizing Ab|
|Study Type:||Antibody Screening|
|Study Start Date:||2015-09-30|
|Study Made Public:||2016-12-16|
Neutralization of eCD4-Ig variants 1v34 and 2v26
CAVD 521 is a monoclonal antibody screening study evaluating the neutralization of IC50s and IC80s using a panel of 200 Clade C isolates (Early/Acute Pseudovirus Panel) for two eCD4-Ig variants.
Sign in to see full information about this study and to download study data.
ProductsNo Products used in study
No integrated data is available for this study.
No non-integrated data is available for this study.